Category: Abicipar pegol

  • AbbVie Terminates its License Agreement with Molecular Partners for Abicipar Pegol

    Shots: AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally, Molecular Partners will reacquire the development and commercial rights of abicipar globally Molecular Partners will put a special committee to assess the program & figure out the next steps. Additionally, the companies will continue the ongoing discovery collaboration to […]